Eiko Lifesciences
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Aug 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
GETS RECOVERY PROCEEDINGS COMMUNICATIONS FROM IDBI BANK OVER ALLEGED CORPORATE GUARANTEE
ALLEGED CORPORATE GUARANTEE OF 5.8 MILLION RUPEES STATED TO BE ISSUED IN 1986
Source text: ID:nBSE90zvJl
Further company coverage: EIKO.BO
(([email protected];))
Aug 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
GETS RECOVERY PROCEEDINGS COMMUNICATIONS FROM IDBI BANK OVER ALLEGED CORPORATE GUARANTEE
ALLEGED CORPORATE GUARANTEE OF 5.8 MILLION RUPEES STATED TO BE ISSUED IN 1986
Source text: ID:nBSE90zvJl
Further company coverage: EIKO.BO
(([email protected];))
Dec 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
ANNOUNCES STRATEGIC DIVERSIFICATION INTO LOGISTICS AND CONTAINER MANAGEMENT
EIKOVIVIFY LOGISTICS ENTERS LONG-TERM SERVICE CONTRACT WITH S J LOGISTICS
EIKOVIVIFY LOGISTICS BUYS 1,000 CONTAINERS UNDER COLLABORATION
Source text: ID:nBSE5qSlrS
Further company coverage: EIKO.BO
(([email protected];;))
Dec 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
ANNOUNCES STRATEGIC DIVERSIFICATION INTO LOGISTICS AND CONTAINER MANAGEMENT
EIKOVIVIFY LOGISTICS ENTERS LONG-TERM SERVICE CONTRACT WITH S J LOGISTICS
EIKOVIVIFY LOGISTICS BUYS 1,000 CONTAINERS UNDER COLLABORATION
Source text: ID:nBSE5qSlrS
Further company coverage: EIKO.BO
(([email protected];;))
Jan 25 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
TO ENTER INTO DEFINITIVE BUSINESS AGREEMENT WITH VIVACIOUS PHARMATEX
Source text for Eikon: ID:nBSE45Bhpw
Further company coverage: EIKO.BO
(([email protected];))
Jan 25 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
TO ENTER INTO DEFINITIVE BUSINESS AGREEMENT WITH VIVACIOUS PHARMATEX
Source text for Eikon: ID:nBSE45Bhpw
Further company coverage: EIKO.BO
(([email protected];))
June 30 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
APPROVED RIGHT ENTITLEMENT RATIO OF 2 SHARE FOR EVERY 3 SHARES HELD
APPROVED RIGHT ISSUE PRICE OF 45 RUPEES PER SHARE
Source text for Eikon: ID:nBSE4QrjDq
Further company coverage: EIKO.BO
(([email protected];;))
June 30 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
APPROVED RIGHT ENTITLEMENT RATIO OF 2 SHARE FOR EVERY 3 SHARES HELD
APPROVED RIGHT ISSUE PRICE OF 45 RUPEES PER SHARE
Source text for Eikon: ID:nBSE4QrjDq
Further company coverage: EIKO.BO
(([email protected];;))
May 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
ACQUIRED 25.01% STAKE IN REFLUX PHARMACEUTICALS
Source text for Eikon: ID:nBSE19mJhh
Further company coverage: EIKO.BO
(([email protected];))
May 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
ACQUIRED 25.01% STAKE IN REFLUX PHARMACEUTICALS
Source text for Eikon: ID:nBSE19mJhh
Further company coverage: EIKO.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Eiko Lifesciences do?
Eiko LifeSciences Ltd is a manufacturer of speciality and fine chemicals, pharma and agro intermediates. It focuses on R&D-driven growth and diversification into APIs, oleochemicals, and logistics.
Who are the competitors of Eiko Lifesciences?
Eiko Lifesciences major competitors are Malpani Pipe&Fitting, AVSL Industries, Indian Emulsifiers, Renol Polychem, Polychem, Sunil Healthcare, Shentracon Chemicals. Market Cap of Eiko Lifesciences is ₹67 Crs. While the median market cap of its peers are ₹74 Crs.
Is Eiko Lifesciences financially stable compared to its competitors?
Eiko Lifesciences seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Eiko Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Eiko Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Eiko Lifesciences allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Eiko Lifesciences balance sheet?
Balance sheet of Eiko Lifesciences is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Eiko Lifesciences improving?
Yes, profit is increasing. The profit of Eiko Lifesciences is ₹5.64 Crs for TTM, ₹2.11 Crs for Mar 2025 and ₹0.75 Crs for Mar 2024.
Is the debt of Eiko Lifesciences increasing or decreasing?
Yes, The net debt of Eiko Lifesciences is increasing. Latest net debt of Eiko Lifesciences is -₹8.88 Crs as of Mar-26. This is greater than Mar-25 when it was -₹20.8 Crs.
Is Eiko Lifesciences stock expensive?
Eiko Lifesciences is not expensive. Latest PE of Eiko Lifesciences is 13.13, while 3 year average PE is 71.26. Also latest EV/EBITDA of Eiko Lifesciences is 7.39 while 3yr average is 43.83.
Has the share price of Eiko Lifesciences grown faster than its competition?
Eiko Lifesciences has given lower returns compared to its competitors. Eiko Lifesciences has grown at ~-18.46% over the last 1yrs while peers have grown at a median rate of -13.0%
Is the promoter bullish about Eiko Lifesciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Eiko Lifesciences is 39.91% and last quarter promoter holding is 39.91%.
Are mutual funds buying/selling Eiko Lifesciences?
There is Insufficient data to gauge this.